Translational evidence for a role of endocannabinoids in the etiology and treatment of posttraumatic stress disorder

Psychoneuroendocrinology

Volumn 51, Issue , 2015, Pages 577-584

  Neumeister, Alexander ^a   Seidel, Jordan ^a   Ragen, Benjamin J ^a   Pietrzak, Robert H ^b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 Factor PTSD model; Anxious arousal; Endocannabinoids; PTSD; Treatment

Indexed keywords

ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; DRONABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE INHIBITOR;

AMYGDALOID NUCLEUS; ANXIETY; AROUSAL; ARTICLE; CARDIOVASCULAR DISEASE; CHRONICITY; COGNITIVE DEFECT; DISEASE SEVERITY; DRUG MECHANISM; DYSPHORIA; EMOTIONAL DISORDER; EVIDENCE BASED MEDICINE; FAINTNESS; HIGH RISK POPULATION; HUMAN; HYPERAROUSAL; HYPERPHAGIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MENTAL DISEASE; MORBIDITY; NERVE CELL NETWORK; NEUROIMAGING; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPIC VARIATION; POLYPHARMACOLOGY; POSTTRAUMATIC STRESS DISORDER; PROTEIN FUNCTION; PSYCHOTHERAPY; SEX DIFFERENCE; SUICIDAL BEHAVIOR; SURVIVOR; SYMPTOMATOLOGY; TACHYCARDIA; THREAT; TRANSLATIONAL RESEARCH; ANIMAL; BRAIN; DISEASE MODEL; METABOLISM; STRESS DISORDERS, POST-TRAUMATIC;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; HUMANS; RECEPTOR, CANNABINOID, CB1; STRESS DISORDERS, POST-TRAUMATIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84920565819     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2014.10.012     Document Type: Article

References (84)

1. Armour C., Carragher N., Elhai J.D. Assessing the fit of the dysphoric arousal model across two nationally representative epidemiological surveys: the Australian NSMHWB and the United States NESARC. J. Anxiety Disord. 2012, 27:109-115.
2. 1 receptor antagonism. Neurobiol. Dis. 2010, 39:148-155.
3. Bowler, R.M., Han, H., Gocheva, V., Nakagawa, S., Alper, H., Digrande, L., Cone, J.E., 2012, Gender differences in probable posttraumatic stress disorder among police responders to the 2001 World Trade Center terrorist attack. Am. J. Ind. Med. 53, 1186-1196.
4. Brady K., Pearlstein T., Asnis G.M., Baker D., Rothbaum B., Sikes C.R., Farfel G.M. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000, 283:1837-1844.
5. Breslau N. Gender differences in trauma and posttraumatic stress disorder. J. Gend. Specifc Med. 2002, 5:34-40.
6. Breslau N., Anthony J.C. Gender differences in the sensitivity to posttraumatic stress disorder: an epidemiological study of urban young adults. J. Abnorm. Psychol. 2007, 116:607-611.
7. Chhatwal J.P., Davis M., Maguschak K.A., Ressler K.J. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 2005, 30:516-524.
8. Contractor A.A., Durham T.A., Brennan J.A., Armour C., Wutrick H.R., Frueh B.C., Elhai J.D. DSM-5 PTSD's symptom dimensions and relations with major depression's symptom dimensions in a primary care sample. Psychiatry Res. 2014, 215:146-153.
9. Cornelius, J.R., Kirisci, L., Reynolds, M., Clark, D.B., Hayes, J., Tarter, R., 2010. PTSD contributes to teen and young adult cannabis use disorders. Addict. Behav. 35, 91-94.
10. Davidson J., Baldwin D., Stein D.J., Kuper E., Benattia I., Ahmed S., Pedersen R., Musgnung J. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch. Gen. Psychiatry 2006, 63:1158-1165.
11. Davidson J., Rothbaum B.O., Tucker P., Asnis G., Benattia I., Musgnung J.J. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J. Clin. Psychopharmacol. 2006, 26:259-267.
12. Davidson J.R., Rothbaum B.O., Van Der Kolk B.A., Sikes C.R., Farfel G.M. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch. Gen. Psychiatry 2001, 58:485-492.
13. Dell'osso, L., Carmassi, C., Massimetti, G., Daneluzzo, E., Di Tommaso, S., Rossi, A., 2011. Full and partial PTSD among young adult survivors 10 months after the L'Aquila 2009 earthquake: Gender differences. J. Affect. Disord. Jun;131(1-3):79-83. doi: 10.1016/j.jad.2010.11.023. Epub 2011 Jan 26.
14. Ditlevsen, D.N., Elklit, A., 2010. The combined effect of gender and age on post traumatic stress disorder: do men and women show differences in the lifespan distribution of the disorder? Ann. Gen. Psychiatry 9, Jul 21;9:32. doi: 10.1186/1744-859X-9-32.
15. Elhai J.D., Biehn T.L., Armour C., Klopper J.J., Frueh B.C., Palmieri P.A. Evidence for a unique PTSD construct represented by PTSD's D1-D3 symptoms. J. Anxiety Disord. 2011, 25:340-345.
16. Fani N., Tone E.B., Phifer J., Norrholm S.D., Bradley B., Ressler K.J., Kamkwalala A., Jovanovic T. Attention bias toward threat is associated with exaggerated fear expression and impaired extinction in PTSD. Psychol. Med. 2012, 42:533-543.
17. Fattore L., Fratta, W., 2010. How important are sex differences in cannabinoid action? Br. J. Pharmacol. Jun;160(3):544-8. doi: 10.1111/j.1476-5381.2010.00776.x.
18. Fraser G.A. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci. Ther. 2009, 15:84-88.
19. Freedy, J.R., Magruder, K.M., Mainous, A.G., Frueh, B.C., Geesey, M.E., Carnemolla, M., 2010. Gender differences in traumatic event exposure and mental health among veteran primary care patients. Mil. Med. Oct;175(10):750-758.
20. Friedman M.J., Marmar C.R., Baker D.G., Sikes C.R., Farfel G.M. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a department of veterans affairs setting. J. Clin. Psychiatry 2007, 68:711-720.
21. Galovski, T.E., Mott, J., Young-XU, Y., Resick, P.A., 2011. Gender differences in the clinical presentation of PTSD and its concomitants in survivors of interpersonal assault. J. Interpers. Violence Mar;26(4):789-806. doi: 10.1177/0886260510365865. Epub 2010 May 24.
22. Garcia-Garcia F., Acosta-Pena E., Venebra-Munoz A., Murillo-Rodriguez E. Sleep-inducing factors. CNS Neurol. Disord. Drug Targets 2009, 8:235-244.
23. GEUZE, E., WESTENBERG, H. G., JOCHIMS, A., DE KLOET, C. S., BOHUS, M., VERMETTEN, E. SCHMAHL, C. 2007. Altered pain processing in veterans with posttraumatic stress disorder. Arch Gen Psychiatry, 64, 76-85.
24. Glass M., Dragunow M., Faull R.L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. NeuroScience 1997, 77:299-318.
25. Gorzalka B.B., Hill M.N., Hillard C.J. Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. Neurosci. Biobehav. Rev. 2008, 32:1152-1160.
26. Grillon C., Southwick S.M., Charney D.S. The psychobiological basis of posttraumatic stress disorder. Mol. Psychiatry 1996, 1:278-297.
27. Gunduz-Cinar O., Hill M.N., Mcewen B.S., Holmes A. Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol. Sci. 2013, 34:637-644.
28. Gunduz-Cinar O., Macpherson K.P., Cinar R., Gamble-George J., Sugden K., Williams B., Godlewski G., Ramikie T.S., Gorka A.X., Alapafuja S.O., Nikas S.P., Makriyannis A., Poulton R., Patel S., Hariri A.R., Caspi A., Moffitt T.E., Kunos G., Holmes A. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol. Psychiatry 2013, 18:813-823.
29. 1 cannabinoid receptor on anxiety. Eur. J. Neurosci. 2002, 16:1395-1398.
30. 1-specific agents. Behav. Pharmacol. 2004, 15:299-304.
31. Harpaz-Rotem I., Tsai J., Pietrzak R.H., Hoff R. The dimensional structure of posttraumatic stress symptomatology in 323,903 U.S. veterans. J. Psychiatr. Res. 2014, 49:31-36.
32. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., De Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:1932-1936.
33. Hill M.N., Bierer L.M., Makotkine I., Golier J.A., Galea S., Mcewen B.S., Hillard C.J., Yehuda R. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks. Psychoneuroendocrinology 2013, 38:2952-2961.
34. Hill M.N., Carrier E.J., Mclaughlin R.J., Morrish A.C., Meier S.E., Hillard C.J., Gorzalka B.B. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J. Neurochem. 2008, 106:2322-2336.
35. Hill M.N., Karacabeyli E.S., Gorzalka B.B. Estrogen recruits the endocannabinoid system to modulate emotionality. Psychoneuroendocrinology 2007, 32:350-357.
36. Hill, M.N., Mclaughlin, R.J., Bingham, B., Shrestha, L., Lee, T.T., Gray, J.M., Hillard, C.J., Gorzalka, B.B., Viau, V., 2010. Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl. Acad. Sci. U.S.A., 107, 9406-9411. doi: 10.1073/pnas.0914661107. Epub 2010 May 3.
37. Hill M.N., Miller G.E., Carrier E.J., Gorzalka B.B., Hillard C.J. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 2009, 34:1257-1262.
38. Hill M.N., Miller G.E., HO W.S., Gorzalka B.B., Hillard C.J. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 2008, 41:48-53.
39. Hill M.N., Patel S., Carrier E.J., Rademacher D.J., Ormerod B.K., Hillard C.J., Gorzalka B.B. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005, 30:508-515.
40. Hirvonen, J., Goodwin, R.S., Li, C.T., Terry, G.E., Zoghbi, S.S., Morse, C., Pike, V.W., Volkow, N.D., Huestis, M.A., Innis, R.B., 2012. Reversible and regionally selective downregulation of brain cannabinoid CB(1) receptors in chronic daily cannabis smokers. Mol. Psychiatry. Jun;17(6):642-9. doi: 10.1038/mp.2011.82. Epub 2011 Jul 12.
41. Hoge C.W., Castro C.A., Messer S.C., Mcgurk D., Cotting D.I., Koffman R.L. Combat duty in Iraq and Afghanistan, mental health problems and barriers to care. US Army Med. Dep. J. 2008, 7-17.
42. Irish, L.A., Fischer, B., Fallon, W., Spoonster, E., Sledjeski, E.M., Delahanty, D.L. Gender differences in PTSD symptoms: an exploration of peritraumatic mechanisms. J. Anxiety Disord. 25, 209-216.
43. Ipser JC, Stein DJ., 2012, Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD)., Int J Neuropsychopharmacol., 15(6):825-40. doi: 10.1017/S1461145711001209. Epub 2011 Jul 29. Review.
44. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 2005, 62:617-627.
45. Kessler R.C., Sonnega A., Bromet E., Hughes M., Nelson C.B. Posttraumatic stress disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry 1995, 52:1048-1060.
46. Kirilly E., Hunyady L., Bagdy G. Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB(1) receptor antagonists. J. Neural. Transm. 2013, 120:177-186.
47. Klugmann, M., Klippenstein, V., Leweke, F.M., Spanagel, R., Schneider, M. Cannabinoid exposure in pubertal rats increases spontaneous ethanol consumption and NMDA receptor associated protein levels. Int. J. Neuropsychopharmacol., 14, 505-517.
48. Krebs-Kraft, D.L., Hill, M.N., Hillard, C.J. & Mccarthy, M.M. Sex difference in cell proliferation in developing rat amygdala mediated by endocannabinoids has implications for social behavior. Proc. Natl. Acad. Sci. U.S.A., 107, 20535-20540.
49. Krystal J.H., Rosenheck R.A., Cramer J.A., Vessicchio J.C., Jones K.M., Vertrees J.E., Horney R.A., Huang G.D., Stock C. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA 2011, 306:493-502.
50. Ledoux J.E. Emotion circuits in the brain. Annu. Rev. Neurosci. 2000, 23:155-184.
51. Leweke F.M., Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict. Biol. 2008, 13:264-275.
52. Lindqvist D., Wolkowitz O.M., Mellon S., Yehuda R., Flory J.D., Henn-Haase C., Bierer L.M., Abu-Amara D., Coy M., Neylan T.C., Makotkine I., Reus V.I., Yan X., Taylor N.M., Marmar C.R., Dhabhar F.S. Proinflammatory milieu in combat-related PTSD is independent of depression and early life stress. Brain Behav. Immun. 2014, doi: 10.1016/j.bbi.2014.06.003, pii: S0889-1591(14)00166-4. [Epub ahead of print].
53. Lindstrom K.M., Mandell D.J., Musa G.J., Britton J.C., Sankin L.S., Mogg K., Bradley B.P., Ernst M., Doan T., Bar-Haim Y., Leibenluft E., Pine D.S., Hoven C.W. Attention orientation in parents exposed to the 9/11 terrorist attacks and their children. Psychiatry Res. 2011, 187:261-266.
54. Luxton, D.D., Skopp, N.A., Maguen, S., 2010. Gender differences in depression and PTSD symptoms following combat exposure. Depress. Anxiety 27, 1027-1033.
55. Marshall R.D., Beebe K.L., OLDHAM M., Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am. J. Psychiatry 2001, 158:1982-1988.
56. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., Hofmann C., Zieglgansberger W., Marzo D.I., Lutz V.B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418:530-534.
57. Mclean, C.P., Asnaani, A., Litz, B.T., Hofmann, S.G., 2011. Gender differences in anxiety disorders: Prevalence, course of illness, comorbidity and burden of illness. J. Psychiatr. Res. Aug;45(8):1027-35. doi: 10.1016/j.jpsychires.2011.03.006. Epub 2011 Mar 25.
58. Neumeister A. The endocannabinoid system provides an avenue for evidence-based treatment development for PTSD. Depress. Anxiety 2013, 30:93-96.
59. 1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol. Psychiatry 2013, 18:1034-1040.
60. Passie T., Emrich H.M., Karst M., Brandt S.D., Halpern J.H. Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Anal. 2012, 4:649-659.
61. Petrosino S., Marzo D.I.V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr. Opin. Investig. Drugs 2010, 11:51-62.
62. Phelps E.A., Ledoux J.E. Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron 2005, 48:175-187.
63. Pietrzak R.H., Gallezot J.D., Ding Y.S., Henry S., Potenza M.N., Southwick S.M., Krystal J.H., Carson R.E., Neumeister A. Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus. JAMA Psychiatry 2013, 70:1199-1205.
64. Pietrzak R.H., Goldstein R.B., Southwick S.M., Grant B.F. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J. Anxiety Disord. 2011, 25:456-465.
65. Pietrzak R.H., Henry S., Southwick S.M., Krystal J.H., Neumeister A. Linking in vivo brain serotonin type 1B receptor density to phenotypic heterogeneity of posttraumatic stress symptomatology. Mol. Psychiatry 2013, 18:399-401.
66. Pietrzak R.H., Huang Y., Corsi-Travali S., Zheng M.Q., Lin S.F., Henry S., Potenza M.N., Piomelli D., Carson R.E., Neumeister A. Cannabinoid Type 1 receptor availability in the amygdala mediates threat processing in trauma survivors. Neuropsychopharmacology 2014.
67. Pietrzak R.H., Tsai J., Harpaz-Rotem I., Whealin J.M., Southwick S.M. Support for a novel five-factor model of posttraumatic stress symptoms in three independent samples of Iraq/Afghanistan veterans: a confirmatory factor analytic study. J. Psychiatr. Res. 2012, 46:317-322.
68. Rademacher D.J., Meier S.E., Shi L., HO W.S., Jarrahian A., Hillard C.J. Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice. Neuropharmacology 2008, 54:108-116.
69. Rauch S.L., Shin L.M., Phelps E.A. Neurocircuitry models of posttraumatic stress disorder and extinction: human neuroimaging research-past, present, and future. Biol. Psychiatry 2006, 60:376-382.
70. 1 receptors in male and female rats. Behav. Brain Res. 2009, 203:264-269.
71. Roberts C.J., Stuhr K.L., Hutz M.J., Raff H., Hillard C.J. Endocannabinoid signaling in hypothalamic-pituitary-adrenocortical axis recovery following stress: effects of indirect agonists and comparison of male and female mice. Pharmacol. Biochem. Behav. 2014, 117:17-24.
72. Rodrigues S.M., Schafe G.E., Ledoux J.E. Molecular mechanisms underlying emotional learning and memory in the lateral amygdala. Neuron 2004, 44:75-91.
73. Rogan M.T., Staubli U.V., Ledoux J.E. Fear conditioning induces associative long-term potentiation in the amygdala. Nature 1997, 390:604-607.
74. Roitman P., Mechoulam R., Cooper-Kazaz R., Shalev A. Preliminary, open-label, pilot study of add-on oral Delta9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin. Drug Investig. 2014, 34:587-591.
75. Schnurr P.P., Lunney C.A. Exploration of gender differences in how quality of life relates to posttraumatic stress disorder in male and female veterans. J. Rehabil. Res. Dev. 2008, 45:383-393.
76. Stein D.J., Ipser J.C., Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst. Rev. 2006, CD002795.
77. Stein M.B., Walker J.R., Forde D.R. Gender differences in susceptibility to posttraumatic stress disorder. Behav. Res. Ther. 2000, 38:619-628.
78. Suarez J., Llorente R., Romero-Zerbo S.Y., Mateos B., Bermudez-Silva F.J., Fonseca D.E., Viveros F.R.M.P. Early maternal deprivation induces gender-dependent changes on the expression of hippocampal CB(1) and CB(2) cannabinoid receptors of neonatal rats. Hippocampus 2009, 19:623-632.
79. Sveen J., Dyster-Aas J., Willebrand M. Attentional bias and symptoms of posttraumatic stress disorder one year after burn injury. J. Nerv. Ment. Dis. 2009, 197:850-855.
80. Thomas J.L., Wilk J.E., Riviere L.A., Mcgurk D., Castro C.A., Hoge C.W. Prevalence of mental health problems and functional impairment among active component and National Guard soldiers 3 and 12 months following combat in Iraq. Arch. Gen. Psychiatry 2010, 67:614-623.
81. Tsai, J., Harpaz-Rotem, I., Armour, C., Southwick, S.M., Krystal, J.H., Pietrzak, R.H. Dimensional structure of DSM-5 posttraumatic stress symptoms: results from the National Health and Resilience in Veterans Study. J. Clin. Psychiatry.
82. Tsai J., Whealin J.M., Scott J.C., Harpaz-Rotem I., Pietrzak R.H. Examining the relation between combat-related concussion, a novel 5-factor model of posttraumatic stress symptoms, and health-related quality of life in Iraq and Afghanistan veterans. J. Clin. Psychiatry 2012, 73:1110-1118.
83. Varvel S.A., Wise L.E., Niyuhire F., Cravatt B.F., Lichtman A.H. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology 2007, 32:1032-1041.
84. Vetter S., Rossegger A., Rossler W., Bisson J.I., Endrass J. Exposure to the tsunami disaster PTSD symptoms and increased substance use-an Internet based survey of male and female residents of Switzerland. BMC Public Health 2008, 8:92.